{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marcocci C"],"funding":["NIDDK NIH HHS"],"pagination":["2766-72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3214593"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["94(8)"],"pubmed_abstract":["<h4>Context</h4>Patients with persistent primary hyperparathyroidism (PHPT) after parathyroidectomy or with contraindications to parathyroidectomy often require chronic treatment for hypercalcemia.<h4>Objective</h4>The objective of the study was to assess the ability of the calcimimetic, cinacalcet, to reduce serum calcium in patients with intractable PHPT.<h4>Design</h4>This was an open-label, single-arm study comprising a titration phase of variable duration (2-16 wk) and a maintenance phase of up to 136 wk.<h4>Setting</h4>The study was conducted at 23 centers in Europe, the United States, and Canada.<h4>Patients</h4>The study included 17 patients with intractable PHPT and serum calcium greater than 12.5 mg/dl (3.1 mmol/liter).<h4>Intervention</h4>During the titration phase, cinacalcet d"],"journal":["The Journal of clinical endocrinology and metabolism"],"pubmed_title":["Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism."],"pmcid":["PMC3214593"],"funding_grant_id":["R01 DK032333"],"pubmed_authors":["Henzen C","Cheng S","Orgiazzi J","Lu J","Shoback D","Bilezikian J","Sterling LR","Marcocci C","Chanson P","Peacock M","Fernandez-Cruz L"],"additional_accession":[]},"is_claimable":false,"name":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.","description":"<h4>Context</h4>Patients with persistent primary hyperparathyroidism (PHPT) after parathyroidectomy or with contraindications to parathyroidectomy often require chronic treatment for hypercalcemia.<h4>Objective</h4>The objective of the study was to assess the ability of the calcimimetic, cinacalcet, to reduce serum calcium in patients with intractable PHPT.<h4>Design</h4>This was an open-label, single-arm study comprising a titration phase of variable duration (2-16 wk) and a maintenance phase of up to 136 wk.<h4>Setting</h4>The study was conducted at 23 centers in Europe, the United States, and Canada.<h4>Patients</h4>The study included 17 patients with intractable PHPT and serum calcium greater than 12.5 mg/dl (3.1 mmol/liter).<h4>Intervention</h4>During the titration phase, cinacalcet d","dates":{"release":"2009-01-01T00:00:00Z","publication":"2009 Aug","modification":"2026-04-12T23:44:05.975Z","creation":"2019-03-27T00:01:09Z"},"accession":"S-EPMC3214593","cross_references":{"pubmed":["19470620"],"doi":["10.1210/jc.2008-2640"]}}